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SCIENTIFIC LETTER

Prevalence of gastric mucosal interleukin-1 polymorphisms
in Kenyan patients with advanced gastric cancer
Kimang’a Nyerere, Shahin Sayed, Gunturu Revathi, Peter Ojwang, Viviene Matiru, Smita Devani, Mahesh Shah, Samuel Kariuki
To the Editor: Helicobacter pylori is the main cause of peptic
ulceration, distal gastric adenocarcinoma, and gastric
lymphoma.1 Worldwide, gastric cancer is the second most
common malignancy in men and women.1 According to data
from the Nairobi Cancer Registry, gastric cancer is the fourth
most common malignancy in adult males and the fifth most
common in adult females. However, this may not represent
the true situation because of under-reporting of cases. In the
development of gastric cancer, environmental factors such as
smoking, diet and, in particular, infection with H. pylori are
significant.1 Based on epidemiological studies, the International
Agency for Research on Cancer (IARC) identified H. pylori as
a ‘group 1 agent (definite carcinogen)’.2 H. pylori infection can
result in decreased acid secretion with subsequent mucosal
atrophy and intestinal metaplasia.1 Another precondition for
mucosal atrophy is autoimmunity against parietal cells, which
can mimic classic autoimmune gastritis with the presence
of various autoantibodies in up to 40% of H. pylori-infected
individuals.1
The occurrence of intestinal metaplasia, for which a
relationship with gastric cancer is strongly suggested, has
been demonstrated in approximately 60% of patients with
H. pylori infection.1 The metaplasia may then progress to
gastric cancer, especially to tumours of the intestinal type.1
Findings by Uemura et al. support the importance of these
histological findings as a precancerous condition in H. pyloriassociated gastritis.3 However, only a minority of H. pylori-
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infected patients develop gastric cancer, which underscores
the notion that the host genetic background could be of critical
importance.
Data strongly suggest that the susceptibility to infection
from H. pylori is mainly conferred by genes involved in
inflammatory processes following colonisation with H.
pylori.1 Chronic gastritis is characterised by the release of
pro-inflammatory cytokines such as interleukin-1β (IL-1β)
or tumour-necrosis factor alpha (TNFα), which are potent
inhibitors of gastric acid secretion.1 Advanced-stage gastric
cancer has been repeatedly associated with polymorphisms
of the IL-1 gene cluster on chromosome 2q, which contains
3 related genes within a 430 kb region (IL-1A, IL-1B, and
IL-1RN), encoding for IL-1α , IL-1β, and the endogenous
receptor antagonist IL-1ra, respectively. It was hypothesised
that genetic differences within these genes could influence
the immune response against pathogens such as H. pylori and
the development of premalignant histological alterations in
the gastric mucosa.1 In patients with advanced-stage gastric
cancer, an increased frequency of the IL-1B-31C and IL-1B-511T
alleles and the uncommon IL-1B-31C/IL-1B-511T haplotype
was demonstrated. In addition, the IL-1RN*2 allele and the
homozygous genotype IL-1RN*2/2 were found in increased
prevalence in gastric cancers.1 Subsequent studies confirmed
these genetic associations.1 El-Omar et al. genotyped patients
with gastric cancer according to tumour localisation (cardia
v. non-cardia) and oesophageal cancers (adenocarcinomas
v. squamous cell carcinomas) for various polymorphisms of
genes encoding for pro- and anti-inflammatory cytokines.4
They described an increased risk for non-cardia gastric cancer
in carriers of the IL-1B-511T allele, IL-1RN*2 homozygotes,
carriers of the TNF-A-308A allele and the haplotype IL-101082A/-819T/-592A. The cumulative risk depends on the
number of high-risk alleles or genotypes per patient.4 A
previous study confirmed the risk increase for development
of gastric carcinoma in carriers of multiple proinflammatory
genotypes.1 The alleles IL-1RN*2 and IL-1B-511T are associated
with increased synthesis of the proinflammatory cytokine
IL-1ß, and the allele TNFA-308A results in an increased
production of the proinflammatory cytokine TNF.1

Patients and methods
The study used 41 archival paraffin-embedded gastric cancer
tissue blocks obtained in 2007 from endoscopic biopsies and
gastrectomies. Haematoxylin and eosin-stained slides were
reviewed and the tumours classified according to the WHO
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Center for the International Histological Classification of
Tumors. DNA was extracted using the QIAamp DNA kit.
The study was approved by the Aga Khan University (East
Africa) Research and Ethics Committee. The H. pylori status
was determined by polymerase chain reaction (PCR) using
the ureA gene according to the method of Miyabayashi
et al.5 The ureA region was amplified using the following
primers: 5’-AAGCTTTTAGGGGTGTTAGGGGTTT-3’.
The IL-1B fragment was amplified using the following
primers: 5’- TGGCATTGATCTGGTTCATC-3’ and 5’GTTTAGGAATCTTCCCACTT-3’, while the IL-1RN intron
2 containing a penta-allelic 86-bp tandem repeats (VNTR)
DNA oligonucleotides 5’-CTCAGCAACACTCCTAT-3’ and 5’TCCTGGTCTGCAGGTAA-3’ flanking this region were used as
primers.
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Data analysis
Statistical analysis to determine the relationship between
variables was performed using the chi-square test with
p-values less than 0.005 considered as significant. Linear
regression determined how independent factors predicted the
outcome of dependent factors.

Results
We analysed 41 gastric biopsy samples that were preserved in
formalin and embedded in paraffin wax, obtained over a year.
All the biopsies were of adult Kenyan patients with advanced
gastric cancer; 31 (76%) were of the intestinal type and 24%
were of the diffuse ‘signet ring’ type; 26 (63%) were from male
and 15 (37%) from female patients; their ages ranged from 36
years to 76 years, with 56% <50 years of age. We screened for
the frequencies of genotypes and alleles of IL-1B and IL-1RN
in these cancer tissues. Overall, 19 (46%) patients had IL-1RN
while 18 (43%) had IL-1B. When analysed, the IL-1RN found
in the Kenyan gastric cancer population only showed allele IL1RN 1*4 (Fig. 1).
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cancer, as in our cases, the serology is often negative and the
genes will almost always not be detectable by PCR.

In contrast, when IL-1B was analysed by PCR-RFLP
(restriction fragment length polymorphism) method, it gave
products that either remained intact (allele 2; IL-1B-511*2) or
were cut into two fragments of 190 and 114 bp (allele 1; IL-1B511*1) (Fig. 2).

No significant relationship was found between age and
either IL-1RN or IL-1B in gastric carcinoma from Kenyan
patients; the chi-square test for both was not significant: p=0.9
for IL-1RN and p=1.0 for IL-1B, against a significance level of
0.3 and 0.2 respectively. This indicates that these variables are
probably independent of each other. Similarly, there was no
relationship between gender and the occurrence of either IL1RN or IL-1B. Linear regression also showed that neither age
nor gender influenced the expression of IL-1RN or IL-1B.

The H. pylori gene was present in only 6 of the 41 samples.
This was expected because, when H. pylori has been present
for many years and the stomach becomes atrophic and
hypochlorhydric, the intragastric environment is no longer
optimal for H. pylori. Competing faecal-type organisms are
then able to colonise the stomach. Furthermore, H. pylori is
able to colonise only normal gastric cells, and not those that
have differentiated into intestinal metaplasia. Therefore,
H. pylori disappears from the stomach when atrophy and
intestinal metaplasia supervene. In patients who are most
likely to develop gastric cancer (those with extensive intestinal
metaplasia and atrophy) and those already with advanced

The situation differs, however, concerning the relationship
between IL-1RN and IL-1B. The large chi-square statistic
(8.021) and a small significance level (0.005) indicate that it is
unlikely that these variables are independent of each other.
Therefore, we concluded that there is a relationship between
the occurrence of IL-1RN and IL-1B. Linear regression showed
an R-value of 0.45, which indicates that a great deal of variance
is shared by IL-1RN and IL-1B. Analysis of variance (ANOVA)
obtained from the regression F=9.5 appears to indicate that the
predictor variable IL-1RN is not equal to the dependent factor
IL-1B, and that the presence of IL-IRN could be used to predict
the presence of IL-1B.
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Discussion
Instrumental in the development of H. pylori-related gastric
carcinogenesis are some pro-inflammatory cytokines such as
interleukin 1 beta (IL-1β) and interleukin 1 receptor antagonist
(IL-1ra). The interleukin-1 (IL-1) gene cluster on chromosome
2q contains 3 related genes within a 340-kilobase (kb) region,
IL-1A, IL-1B and IL-1RN, which encodes the pro-inflammatory
cytokines IL-1α and IL-1β as well as their endogenous
receptor antagonist IL-1ra respectively.6 IL-1β is up-regulated
in the presence of H. pylori and is important in initiating and
amplifying the inflammatory response to this infection. IL-1β
is also a potent inhibitor of gastric acid secretion. The IL-1RN
gene has penta-allelic 86-bp tandem repeats (VNTR) in intron
2, of which the less common allele 2 (IL-1RN*2) is associated
with a wide range of chronic inflammatory and autoimmune
conditions. IL-1RN*2 is associated with enhanced IL-1β
production.6 Carriers of IL-1RN 2/*2 and IL-1B-511 T have been
reported to be at increased risk of hypochlorhydria and gastric
cancer.6
We tested the hypothesis that IL-1 genetic polymorphisms
are circulating in the Kenyan population and that they
influenced the presence of IL-1B in H. pylori-associated gastric
cancer. Intron 2 of the IL-1RN gene was detected and amplified
by PCR. Homozygous genotype IL-1RN1/*4 was found to be
present. We also observed the IL-1B gene with heterozygous
genotype IL-1B-511*1 and IL-1B-511*2 in our cases of advanced
gastric cancer. This is in contrast with reports from elsewhere
in the world, where IL-1RN 1/*2 has been detected with
increased frequency.7
Il-Ran Hwang et al. found that carriers of IL-1B-511 T/T
genotypes, denoting a single band of 155 bp or IL-1RN*2,
had higher mucosal IL-1β cytokine levels compared with
non-carriers.6 They also observed that carriers of IL-1RN
1/*2 had higher mucosal IL-1β levels than those of IL-1RN
1/*1 consistent with an effect of this polymorphism on
mucosal IL-1β. Also, IL-1RN 1/*2 carriers have atrophy scores
approximately 1 point higher than IL-1RN 1/*1 carriers, which
implies that in IL-1RN 1/*2 carriers atrophy is accelerated such
that the mucosa are functionally 20 years older than the gastric
mucosa of IL-1RN 1/*1 carriers.
IL-1RN*2 allele occurs in the Kenyan population at a much
higher frequency (46.3%), in contrast with reports on Western
and Asian populations.7 For example, the frequency of the IL1RN*2 allele in East Asian countries was lowest (3 - 6%), while
that of the Thai population was 12%. The frequency in Western
populations was reported as 22 - 24%.
Our frequency of the IL-1B-511 allele was lower (18%) than
that reported in the Thai population (34%) but falls within the
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threshold of other populations (15 - 25%).7 These results are
consistent with the notion that in any population, the dominant
factor or combination of factors in relation to gastric cancer
risk among H. pylori-infected individuals will vary and must
be examined directly. Only 6 of our cases tested positive for
H. pylori by gene analysis despite the fact that Ogutu et al.8
reported a prevalence of 80.5% in Kenyan adults presenting
with dyspeptic symptoms and normal endoscopic findings.
This anomaly can be explained by the fact that all our cases
involved advanced carcinomas, and H. pylori is known to
disappear as atrophy and intestinal metaplasia supervene over
a prolonged period of infection.9
In conclusion, this pioneer study of genotype
polymorphisms for interleukin 1 in the Kenyan population
provides evidence that individuals with IL-1B and IL-1RN
polymorphisms associated with H. pylori infection have an
elevated risk of developing gastric cancer. Since it was a pilot
study, the observed significant association could be a chance
observation because of lack of complete clinical information
on the patients whose tissues were used. Our findings require
confirmation by prospective analysis of a larger sample,
looking at other related co-factors.
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